Oncocardiology has gained interest in recent years due to a remarkable increase in the number of new anticancer molecular target drugs causing cardiotoxicity. However, for many anticancer molecular drugs, cardiotoxicity often goes undetected in preclinical safety evaluations. Therefore, tools to improve the preclinical study of many new molecular target compounds are essential for the timely identification of those that are potentially cardiotoxic in clinical treatment. Therefore, a key challenge in the automated assessment of cardiac imaging disturbances with many anticancer molecular trget drugs in zebrafish has been the development of a high-content screening system. The method made use of a transparent, transgenic line of zebrafish expressing green fluorescent protein in the ventricular myocardium. These changes in imaging with each anticancer drug were found to correlate with the clinical cardiotoxicology of each anticancer drug in this study. This automated method was approximately 10 times faster than manual assessment in determining the cardiotoxicity and completely reproduced the results of the manual system. The high throughput and sensitivity of the automated system favors its use over the current manual approaches to oncocardiology. Mol Biotechnol. 2013,55(2):131-42, Toxicol Sci. 2015,143(2):374-84